Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing
Authors:
- 27 November 2021
- journal article
- review article
- Published by SAGE Publications in Dermatitis®
- Vol. 33 (1) , 51-61
Abstract
Background: The underlying mechanisms of residual facial dermatitis on dupilumab (RFDD) in patients dupilumab therapy for atopic dermatitis are poorly understood. Objective: We sought to determine the incidence of RFDD in patients receiving dupilumab and the rate of resolution of RFDD after expanded series patch testing (ESPT) and allergen avoidance. Methods: This is a retrospective chart review of 80 patients with atopic dermatitis who were evaluated for RFDD after treatment with dupilumab. Expanded series patch testing findings and response to allergen avoidance were assessed in the subset of patients with RFDD who subsequently underwent ESPT while continuing to receive dupilumab. Results: Forty-nine patients (61.3%) experienced facial dermatitis before initiating dupilumab. Thirty-five patients (43.8%) experienced RFDD after starting dupilumab. Of the 14 patients with RFDD who received ESPT, 92.9% had 1 or more relevant positive patch test results, with 50% of such patients being mostly to completely clear of facial dermatitis after allergen avoidance. Importantly, 50.6% of the positive reactions to allergens were not included on the North American Contact Dermatitis Group Core 80. Conclusions: Many patients with RFDD benefit from patch testing and subsequent allergen avoidance. Expanded series patch testing should be offered to patients who experience RFDD after beginning dupilumab therapy to ensure that such patients have eliminated any exogenous component of their dermatitis, such as concomitant allergic contact dermatitis.Keywords
This publication has 24 references indexed in Scilit:
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2019
- The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapyJAAD Case Reports, 2018
- Genital Allergic Contact DermatitisDermatitis®, 2018
- Both children and adult patients with difficult‐to‐treat atopic dermatitis have high prevalences of concomitant allergic contact dermatitis and are frequently polysensitizedJournal of the European Academy of Dermatology and Venereology, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- A Pragmatic Approach to Patch Testing Atopic Dermatitis Patients: Clinical Recommendations Based on Expert Consensus OpinionDermatitis®, 2016
- The multiple factors affecting the association between atopic dermatitis and contact sensitizationAllergy, 2013
- The epidemiology of hand eczema in the general population – prevalence and main findings*Contact Dermatitis, 2010
- The role of Malassezia in atopic dermatitis affecting the head and neck of adultsJournal of the American Academy of Dermatology, 2009
- The aetiology of eyelid dermatitis: a 10‐year retrospective analysisContact Dermatitis, 2006